Viemed Healthcare Files 8-K
Ticker: VMD · Form: 8-K · Filed: Sep 23, 2025 · CIK: 1729149
| Field | Detail |
|---|---|
| Company | Viemed Healthcare, Inc. (VMD) |
| Form Type | 8-K |
| Filed Date | Sep 23, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $13.2 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure
Related Tickers: VMD
TL;DR
Viemed Healthcare filed an 8-K, likely with updates. Watch for details.
AI Summary
On September 23, 2025, Viemed Healthcare, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates Viemed Healthcare, Inc. is providing updates or disclosures to the SEC, which could contain material information for investors.
Risk Assessment
Risk Level: low — The provided excerpt is a standard 8-K filing notification without specific details of material events or financial changes.
Key Players & Entities
- VIEMED HEALTHCARE, INC. (company) — Registrant
- September 23, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for Viemed Healthcare, Inc.?
The 8-K filing is for Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is September 23, 2025.
What is Viemed Healthcare, Inc.'s principal executive office address?
The principal executive offices are located at 625 E. Kaliste Saloom Rd., Lafayette, Louisiana 70508.
What is Viemed Healthcare, Inc.'s telephone number?
The registrant's telephone number is (337) 504-3802.
Under which section of the Securities Exchange Act of 1934 is this 8-K filed?
This 8-K is filed pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 588 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2025-09-23 17:01:13
Key Financial Figures
- $13.2 m — gregate purchase price of approximately $13.2 million, before applicable taxes. Item
Filing Documents
- vmd-20250923.htm (8-K) — 34KB
- ex991092325.htm (EX-99.1) — 11KB
- vmdlogo002.jpg (GRAPHIC) — 97KB
- 0001729149-25-000142.txt ( ) — 291KB
- vmd-20250923.xsd (EX-101.SCH) — 2KB
- vmd-20250923_lab.xml (EX-101.LAB) — 20KB
- vmd-20250923_pre.xml (EX-101.PRE) — 12KB
- vmd-20250923_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure Press Release On September 23, 2025, Viemed Healthcare, Inc. (the "Company") issued a press release announcing the completion of its previously authorized share repurchase program, as further described in Item 8.01 below. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information and Exhibit 99.1 be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Other Events
Item 8.01 Other Events On September 23, 2025, the Company announced that it has completed all repurchases authorized under its previously announced share repurchase program. In total, the Company repurchased 1,976,441 common shares for an aggregate purchase price of approximately $13.2 million, before applicable taxes.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits Exhibit Number Description 99.1 Press Release dated September 23, 2025. 104 Cover Page Interactive Data File, formatted in Inline XBRL and included as Exhibit 101
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 23, 2025 VIEMED HEALTHCARE, INC. By: /s/ Trae Fitzgerald Trae Fitzgerald Chief Financial Officer